Treatment Paradigm Could Change
Pfizer's JAK Inhibitor Xeljanz Approved, Set to Launch in RA
Pfizer Inc. is wasting no time with the rollout of its Janus kinase (JAK) inhibitor tofacitinib, branded Xeljanz, which gained FDA approval late Tuesday for adults with moderate to severely active rheumatoid arthritis (RA).
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.